Abstract Library

#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?

Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Julian G

Authors: Gertner J, Groves J, Aziz B, Miah L, Furtado O'Mahony L,

Keywords: prrt,

#2774 Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab

Introduction: Merkel cell carcinoma (MCC) is rare, encompassing primary cutaneous neuroendocrine carcinoma.It has an aggressive natural history, and exhibits high response rates to radiotherapy & chemotherapy but often of short duration.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Demirel S

Authors: Saunders E, Demirel S, Kim S, Skelly R, Mukesh M,

Keywords: merkel cell carcinoma, paraneoplastic syndrome, hyponatraemia,

#2734 Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review

Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Sonbol M, Hilal T, Halfdanarson T,

Keywords: PRRT, t-MN, therapy-related myeloid neoplasm, leukemia, NET, MDS,

#2213 Imaging Modality Depending on the Levels of Tumor Markers

Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Iorio J

Authors: Iorio J, Eleta M, Cuneo L, Polillo D, Peña F,

Keywords: neuroendocrine tumors, tumor marker, 18F-FDOPA, PET/CT,

#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines

Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R,

Keywords: neuroendocrine tumor, GEP-NET, immunophenotyping, copy-number alterations, exome sequencing, inhibitor screening, vorinostat, trametinib,